XNYSCOR
Market cap43bUSD
Dec 24, Last price
227.54USD
1D
-0.04%
1Q
1.84%
Jan 2017
186.68%
Name
Amerisourcebergen Corp
Chart & Performance
Profile
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
IPO date
May 28, 1996
Employees
480
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | 2016‑09 | 2015‑09 | |
Income | ||||||||||
Revenues | 293,958,599 12.12% | 262,173,411 9.89% | 238,587,006 11.50% | |||||||
Cost of revenue | 284,048,570 | 253,213,918 | 230,252,441 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 9,910,029 | 8,959,493 | 8,334,565 | |||||||
NOPBT Margin | 3.37% | 3.42% | 3.49% | |||||||
Operating Taxes | 484,702 | 428,260 | 516,517 | |||||||
Tax Rate | 4.89% | 4.78% | 6.20% | |||||||
NOPAT | 9,425,327 | 8,531,233 | 7,818,048 | |||||||
Net income | 1,509,120 -13.53% | 1,745,293 2.74% | 1,698,820 10.32% | |||||||
Dividends | (416,168) | (398,752) | (391,687) | |||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (1,453,527) | (1,180,728) | 4,598,002 | |||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 576,331 | 641,344 | 1,070,473 | |||||||
Long-term debt | 3,811,745 | 5,994,607 | 5,654,832 | |||||||
Deferred revenue | 5,372,471 | 5,782,032 | ||||||||
Other long-term liabilities | 6,582,381 | 960,486 | 976,583 | |||||||
Net debt | 1,255,428 | 3,980,784 | 3,276,746 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 3,484,685 | 3,911,334 | 2,703,088 | |||||||
CAPEX | (487,173) | (458,359) | (496,318) | |||||||
Cash from investing activities | (618,096) | (2,602,465) | (368,437) | |||||||
Cash from financing activities | (2,330,994) | (2,222,278) | (1,752,780) | |||||||
FCF | 9,199,734 | 11,875,604 | 8,035,003 | |||||||
Balance | ||||||||||
Cash | 3,132,648 | 2,592,051 | 3,388,189 | |||||||
Long term investments | 63,116 | 60,370 | ||||||||
Excess cash | ||||||||||
Stockholders' equity | 4,568,825 | 3,732,151 | 1,432,435 | |||||||
Invested Capital | 11,757,199 | 13,352,292 | 12,454,496 | |||||||
ROIC | 75.07% | 66.12% | 57.81% | |||||||
ROCE | 73.95% | 59.69% | 58.89% | |||||||
EV | ||||||||||
Common stock shares outstanding | 200,284 | 204,591 | 211,210 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 11,028,871 | 9,923,397 | 9,044,400 | |||||||
EV/EBITDA | ||||||||||
Interest | 156,991 | 228,931 | 210,673 | |||||||
Interest/NOPBT | 1.58% | 2.56% | 2.53% |